Side-by-side · Research reference

CartalaxvsCerebrolysin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BPhase 3HUMAN-REVIEWED11/65 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

Cerebrolysin

Porcine Brain-Derived Peptide Mix · Phase 3

30 mL/dayStandard doseAfridi 2026 Staszewski 2026

14–21 daysTreatment course

49% vs 35%mRS 0-2 at 12 moStaszewski 2026

IV infusion · 100-250 mL saline · Daily

01Mechanism of Action

Parameter

Cartalax

Cerebrolysin

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery

Feedback intact?

—

Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids

Antibody development

—

Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented

02Dosage Protocols

Parameter

Cartalax

Cerebrolysin

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

Phase 3 RCT + observational

Standard dose (stroke)

—

30–50 mL / day IVStaszewski 2026 Afridi 2026

Most trials use 30 mL in 100-250 mL saline over 30-60 min.

Lower dose (dementia)

—

10–20 mL / day IV or IMKhatkova 2026

Chronic neurodegenerative conditions; intermittent courses.

High dose (TBI)

—

50 mL / day IVKobayashi 2025

CLINCH trial protocol for intracerebral hemorrhage.

Duration

—

10–21 days (acute); intermittent courses (chronic)

Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.

Timing (stroke)

—

Initiate within 12 hrs of symptom onset; up to 6 hrs optimal

Earlier initiation associated with better outcomes.

Adjunct to thrombectomy

—

30-50 mL daily × 10-14 days, starting day of EVT

Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.

Administration route

—

IV infusion (preferred) or IM injection

IV allows higher doses; IM used in outpatient/chronic settings.

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

Cerebrolysin

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

04Side Effects & Safety

Parameter

Cartalax

Cerebrolysin

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

—

Injection site reaction

—

Mild pain, erythema (IM route)

Infusion reaction

—

Rare: flushing, transient hypotension during rapid IV

Agitation / Restlessness

—

Reported in <5% of patients; typically mild, self-limited

Headache

—

Mild, transient; incidence not significantly elevated vs placeboPatel 2025

Serious adverse events

—

No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)

Hemorrhagic transformation

—

Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025

Mortality

—

No increase; meta-analysis RR 0.89 (0.68-1.18)

Allergic reaction

—

Rare; porcine origin theoretically immunogenic but clinically insignificant

Seizure risk

—

Not elevated; safe in epilepsy populations

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

Cerebrolysin

·Known hypersensitivity to porcine-derived products
·Active seizure disorder (relative — caution advised)

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

Cerebrolysin

·Severe renal impairment (amino acid load — monitor)
·Pregnancy / lactation (insufficient safety data)

05Administration Protocol

Parameter

Cartalax

Cerebrolysin

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.

4. Timing

—

Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.

5. Storage

—

Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.

6. Co-administration

—

Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.

06Stack Synergy

Cartalax

— no documented stacks

Cerebrolysin

+ Semax

Moderate

View Semax →

Cerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.

Cerebrolysin: 30 mL IV daily × 10-14 days
Semax: 300-600 mcg intranasal BID × 10-14 days
Timing: Concurrent during acute recovery phase
Primary benefit: Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI

+ BPC-157

Multi-pathway

View BPC-157 →

Cerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.

Cerebrolysin: 30-50 mL IV daily × 14 days
BPC-157: 250-500 mcg SQ daily × 14-28 days
Timing: Initiate both within 24-48 hrs of injury
Primary benefit: Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery